MaaT Pharma SA (EPA:MAAT)
France · Delayed Price · Currency is EUR 5.72
-0.06 (-1.04%)
Apr 2, 2026, 5:35 PM CET
MaaT Pharma Revenue
In the year 2025, MaaT Pharma had annual revenue of 4.52M EUR with 40.67% growth. MaaT Pharma had revenue of 2.43M in the half year ending June 30, 2025, with 76.12% growth.
Revenue
4.52M
Revenue Growth
+40.67%
P/S Ratio
23.79
Revenue / Employee
69.60K
Employees
65
Market Cap
107.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.52M | 1.31M | 40.67% |
| Dec 31, 2024 | 3.22M | 988.00K | 44.34% |
| Dec 31, 2023 | 2.23M | 798.00K | 55.80% |
| Dec 31, 2022 | 1.43M | 458.00K | 47.12% |
| Dec 31, 2021 | 972.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 67.79M |
| Adocia | 12.88M |
| Fermentalg | 12.78M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Sensorion | 5.81M |
| ABIONYX Pharma | 4.10M |
| Nicox | 3.32M |